Background/PurposeExplaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible patients with acute ischemic stroke (AIS) within a few minutes is important but difficult. We examined whether a new thrombolysis program can decrease the door-to-needle (DTN) time when treating patients with AIS.MethodsA new rtPA thrombolysis program with video assistance was adapted for patients with AIS and their families. We retrospectively compared outcome quality before (2009–2011) and after (2012) the program began. Outcomes included DTN time, the percentage of rtPA thrombolysis within 3 hours of onset in all hospitalized patients with AIS who presented within 2 hours of onset (2hr%) and the percentage of rtPA thrombolys...
BackgroundThe American Heart Association/American Stroke Association (AHA/ ASA) recommended an expan...
Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in...
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it remain...
Background/PurposeExplaining the risks and benefits of recombinant tissue-plasminogen activator (rtP...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
Background and Objective: Attempts have been made to confirm the diagnosis of stroke at the earliest...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and purposeShorter time-to-thrombolysis in acute ischemic stroke (AIS) is associated with...
Background and purposeShorter time-to-thrombolysis in acute ischemic stroke (AIS) is associated with...
Background: Stroke is an abrupt onset of a neurologic deficit due to a focal vascular disease. Treat...
BackgroundThe American Heart Association/American Stroke Association (AHA/ ASA) recommended an expan...
Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in...
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it remain...
Background/PurposeExplaining the risks and benefits of recombinant tissue-plasminogen activator (rtP...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
Background and Objective: Attempts have been made to confirm the diagnosis of stroke at the earliest...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background and purposeShorter time-to-thrombolysis in acute ischemic stroke (AIS) is associated with...
Background and purposeShorter time-to-thrombolysis in acute ischemic stroke (AIS) is associated with...
Background: Stroke is an abrupt onset of a neurologic deficit due to a focal vascular disease. Treat...
BackgroundThe American Heart Association/American Stroke Association (AHA/ ASA) recommended an expan...
Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in...
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it remain...